{"id":"levocetirizine","rwe":[{"pmid":"41724883","year":"2026","title":"Risk of injury associated with the sedative potential of second-generation antihistamines: A nationwide retrospective cohort study.","finding":"","journal":"British journal of clinical pharmacology","studyType":"Clinical Study"},{"pmid":"41709973","year":"2026","title":"Comparative Effects of Anti-Inflammatory Therapies on Olfactory Bulb Histopathology and Olfactory Function in a Rat Model of Experimental Allergic Rhinitis.","finding":"","journal":"Journal of inflammation research","studyType":"Clinical Study"},{"pmid":"41585881","year":"2025","title":"Gender and age variations in neuropsychiatric adverse events of cetirizine and levocetirizine: a disproportionality analysis of ICSRs from FAERS and EudraVigilance data.","finding":"","journal":"Frontiers in pharmacology","studyType":"Clinical Study"},{"pmid":"41505263","year":"2026","title":"Intramuscular Compound Betamethasone for the Emergent Management of Lingual Angioedema.","finding":"","journal":"The Journal of craniofacial surgery","studyType":"Clinical Study"},{"pmid":"41502226","year":"2026","title":"Effect of inhaled corticosteroid with oral montelukast and levocetirizine in asthma: A population-based study.","finding":"","journal":"International journal of clinical pharmacology and therapeutics","studyType":"Clinical Study"}],"_fda":{"id":"6098f8c4-4502-287f-cd05-06e17d773116","set_id":"0216f644-767c-ae88-f48f-cd29ac1547ed","openfda":{"unii":["SOD6A38AGA"],"route":["ORAL"],"rxcui":["855172"],"spl_id":["6098f8c4-4502-287f-cd05-06e17d773116"],"brand_name":["levocetirizine dihydrochloride"],"spl_set_id":["0216f644-767c-ae88-f48f-cd29ac1547ed"],"package_ndc":["68391-955-55","68391-955-11"],"product_ndc":["68391-955"],"generic_name":["LEVOCETIRIZINE DIHYDROCHLORIDE"],"product_type":["HUMAN OTC DRUG"],"substance_name":["LEVOCETIRIZINE DIHYDROCHLORIDE"],"manufacturer_name":["BJWC (Berkley & Jensen / BJ'S)"],"application_number":["ANDA210375"],"original_packager_product_ndc":["43598-735"]},"purpose":["Purpose Antihistamine"],"version":"3","stop_use":["Stop use and ask doctor if you have trouble urinating or emptying your bladder an allergic reaction to this product occurs. Seek medical help right away."],"warnings":["Warnings Do not use if you have kidney disease if you have ever had an allergic reaction to this product or any of its ingredients or to an antihistamine containing cetirizine Ask a doctor before use if you have ever had trouble urinating or emptying your bladder When using this product drowsiness may occur avoid alcoholic drinks alcohol, sedatives, and tranquilizers may increase drowsiness be careful when driving a motor vehicle or operating machinery Stop use and ask doctor if you have trouble urinating or emptying your bladder an allergic reaction to this product occurs. Seek medical help right away. If pregnant or breast-feeding: if breast-feeding: not recommended if pregnant: ask a health professional before use Keep out of reach of children. In case of overdose, get medical help or contact a Poison Control Center right away (1-800-222-1222)."],"questions":["Questions or comments? Call 1-888-375-3784"],"ask_doctor":["Ask a doctor before use if you have ever had trouble urinating or emptying your bladder"],"do_not_use":["Do not use if you have kidney disease if you have ever had an allergic reaction to this product or any of its ingredients or to an antihistamine containing cetirizine"],"when_using":["When using this product drowsiness may occur avoid alcoholic drinks alcohol, sedatives, and tranquilizers may increase drowsiness be careful when driving a motor vehicle or operating machinery"],"effective_time":"20251210","active_ingredient":["Active ingredient (in each tablet) Levocetirizine dihydrochloride USP, 5 mg"],"inactive_ingredient":["Inactive ingredients colloidal silicon dioxide, hypromellose, lactose monohydrate, magnesium stearate, microcrystalline cellulose, polyethylene glycol, titanium dioxide"],"indications_and_usage":["Uses temporarily relieves these symptoms due to hay fever or other respiratory allergies: runny nose sneezing itchy, watery eyes itching of the nose or throat"],"spl_unclassified_section":["Other information store between 20° and 25°C (68° and 77°F) safety sealed: do not use if carton was opened or if printed foil inner seal on bottle is torn or missing"],"dosage_and_administration":["Directions adults 65 years of age and older ask a doctor adults and children 12-64 years of age take 1 tablet (5 mg) once daily in the evening do not take more than 1 tablet (5 mg) in 24 hours 1/2 tablet (2.5 mg) once daily in the evening may be appropriate for less severe symptoms children 6-11 years of age take 1/2 tablet (2.5 mg) once daily in the evening do not take more than 1/2 tablet (2.5 mg) in 24 hours children under 6 years of age do not use consumers with kidney disease do not use"],"spl_product_data_elements":["levocetirizine dihydrochloride levocetirizine dihydrochloride levocetirizine dihydrochloride levocetirizine CELLULOSE, MICROCRYSTALLINE LACTOSE MONOHYDRATE SILICON DIOXIDE MAGNESIUM STEARATE HYPROMELLOSES TITANIUM DIOXIDE Polyethylene Glycol, Unspecified L Stretch card Stretch card Conatiner"],"pregnancy_or_breast_feeding":["If pregnant or breast-feeding: if breast-feeding: not recommended if pregnant: ask a health professional before use"],"keep_out_of_reach_of_children":["Keep out of reach of children. In case of overdose, get medical help or contact a Poison Control Center right away (1-800-222-1222)."],"dosage_and_administration_table":["<table border=\"1\" cellpadding=\"3\" width=\"85%\"><tbody><tr><td> adults 65 years of age and older </td><td><list><item>ask a doctor</item></list></td></tr><tr><td> adults and children 12-64 years of age </td><td><list><item> take 1 tablet (5 mg) once daily in the evening</item><item>do not take more than 1 tablet (5 mg) in 24 hours</item><item> 1/2 tablet (2.5 mg) once daily in the evening may be appropriate for less severe symptoms</item></list></td></tr><tr><td> children 6-11 years of age </td><td><list><item>take 1/2 tablet (2.5 mg) once daily in the evening</item><item>do not take more than 1/2 tablet (2.5 mg) in 24 hours</item></list></td></tr><tr><td> children under 6 years of age </td><td><list><item>do not use</item></list></td></tr><tr><td> consumers with kidney disease </td><td><list><item>do not use</item></list></td></tr></tbody></table>"],"package_label_principal_display_panel":["Levocetirizine Dihydrochloride Tablets, USP 5 mg carton label Levocetirizine Dihydrochloride Tablets USP, 5 mg Antihistamine"]},"tags":[{"label":"Histamine-1 Receptor Antagonist","category":"class"},{"label":"Small Molecule","category":"modality"},{"label":"Histamine H1 receptor","category":"target"},{"label":"HRH1","category":"gene"},{"label":"R06AE09","category":"atc"},{"label":"Topical","category":"route"},{"label":"Oral","category":"route"},{"label":"Cream","category":"form"},{"label":"Gel","category":"form"},{"label":"Shampoo","category":"form"},{"label":"Solution","category":"form"},{"label":"Off-Patent","category":"patent"},{"label":"Generic Available","category":"availability"},{"label":"Mature","category":"status"},{"label":"Allergic rhinitis","category":"indication"},{"label":"Chronic idiopathic urticaria","category":"indication"},{"label":"Seasonal allergic rhinitis","category":"indication"},{"label":"Chattem Sanofi","category":"company"},{"label":"Approved 2000s","category":"decade"},{"label":"Histamine Agents","category":"pharmacology"},{"label":"Histamine Antagonists","category":"pharmacology"},{"label":"Histamine H1 Antagonists","category":"pharmacology"},{"label":"Histamine H1 Antagonists, Non-Sedating","category":"pharmacology"},{"label":"Neurotransmitter Agents","category":"pharmacology"}],"phase":"marketed","safety":{"boxedWarnings":[],"safetySignals":[{"date":"","signal":"DRUG INEFFECTIVE","source":"FDA FAERS","actionTaken":"2988 reports"},{"date":"","signal":"SOMNOLENCE","source":"FDA FAERS","actionTaken":"2121 reports"},{"date":"","signal":"FATIGUE","source":"FDA FAERS","actionTaken":"1663 reports"},{"date":"","signal":"HEADACHE","source":"FDA FAERS","actionTaken":"1326 reports"},{"date":"","signal":"PRURITUS","source":"FDA FAERS","actionTaken":"1210 reports"},{"date":"","signal":"NAUSEA","source":"FDA FAERS","actionTaken":"1082 reports"},{"date":"","signal":"DYSPNOEA","source":"FDA FAERS","actionTaken":"1058 reports"},{"date":"","signal":"DIARRHOEA","source":"FDA FAERS","actionTaken":"1003 reports"},{"date":"","signal":"DIZZINESS","source":"FDA FAERS","actionTaken":"885 reports"},{"date":"","signal":"COUGH","source":"FDA FAERS","actionTaken":"779 reports"}],"commonSideEffects":[{"effect":"Somnolence","drugRate":"","severity":"common","organSystem":""},{"effect":"Nasopharyngitis","drugRate":"","severity":"common","organSystem":""},{"effect":"Fatigue","drugRate":"","severity":"common","organSystem":""},{"effect":"Dry mouth","drugRate":"","severity":"common","organSystem":""},{"effect":"Pharyngitis","drugRate":"","severity":"common","organSystem":""},{"effect":"Pyrexia","drugRate":"","severity":"common","organSystem":""},{"effect":"Cough","drugRate":"","severity":"common","organSystem":""},{"effect":"Epistaxis","drugRate":"","severity":"common","organSystem":""},{"effect":"Diarrhea","drugRate":"","severity":"common","organSystem":""},{"effect":"Vomiting","drugRate":"","severity":"common","organSystem":""},{"effect":"Otitis media","drugRate":"","severity":"common","organSystem":""},{"effect":"Constipation","drugRate":"","severity":"common","organSystem":""}],"contraindications":["Chronic renal failure syndrome","Drowsy","Hemodialysis with High-Flux Membrane","Kidney disease"],"specialPopulations":{"Pregnancy":"There are no adequate and well-controlled studies in pregnant women. Because animal reproduction studies are not always predictive of human response, levocetirizine dihydrochloride should be used during pregnancy only if clearly needed.","Geriatric use":"In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range reflecting the greater frequency of decreased hepatic, renal, or cardiac function and of concomitant disease or other drug therapy with potential for interaction.","Paediatric use":"The recommended dose of levocetirizine for the treatment of the uncomplicated skin manifestations of chronic idiopathic urticaria in patients 12 to 17 years of age is based on extrapolation of efficacy from adults 18 years of age and older.","Renal impairment":"Because levocetirizine dihydrochloride is substantially excreted by the kidneys, the risk of adverse reactions to this drug may be greater in patients with impaired renal function."},"seriousAdverseEvents":[]},"trials":[],"aliases":[],"company":"Sanofi","patents":[],"pricing":[{"market":"United States","source":"CMS National Average Drug Acquisition Cost (NADAC)","asOfDate":"2024-01-03","unitCost":"$0.1030/ML","priceType":"NADAC","sourceUrl":"https://data.medicaid.gov/dataset/4j6z-xnwq","annualCost":"$37","description":"LEVOCETIRIZINE 2.5 MG/5 ML SOL","retrievedDate":"2026-04-07"}],"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=LEVOCETIRIZINE","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-20T00:35:33.208970+00:00"},"timeline":{"url":"https://en.wikipedia.org/wiki/Levocetirizine","method":"deterministic","source":"Wikipedia","rawText":"","confidence":0.8,"sourceType":"wikipedia","retrievedAt":"2026-04-20T00:35:42.229423+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-20T00:35:40.598413+00:00"},"regulatory.us":{"url":"","method":"api_direct","source":"FDA Drugs@FDA","rawText":"","confidence":1,"sourceType":"fda_drugsfda","retrievedAt":"2026-04-20T00:35:32.339383+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=LEVOCETIRIZINE","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-20T00:35:41.168554+00:00"},"administration.route":{"url":"","method":"deterministic","source":"FDA Label","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T00:35:29.662479+00:00"},"safety.boxedWarnings":{"url":"","method":"deterministic","source":"FDA Label (no boxed warning)","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T00:35:29.662512+00:00"},"safety.safetySignals":{"url":"https://api.fda.gov/drug/event.json","method":"api_direct","source":"FDA FAERS","rawText":"","confidence":1,"sourceType":"fda_faers","retrievedAt":"2026-04-20T00:35:42.673407+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL1201191/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T00:35:41.868039+00:00"},"regulatory.fda_application":{"url":"","method":"deterministic","source":"FDA Label","rawText":"ANDA210375","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T00:35:29.662515+00:00"}},"allNames":"xyzal","offLabel":[],"synonyms":["levocetirizine hydrochloride","xyzal","levocetirizine","levocetirizine dihydrochloride","(R)-cetirizine","levocetirizine HCl"],"timeline":[{"date":"2007-01-01","type":"neutral","source":"FDA Orange Book","milestone":"Rights transferred from UCB INC to Chattem Sanofi"},{"date":"2007-05-25","type":"positive","source":"DrugCentral","milestone":"FDA approval (Ucb Inc)"},{"date":"2017-01-31","type":"positive","source":"FDA Orange Book","milestone":"Xyzal Allergy 24Hr approved — 2.5MG/5ML"},{"date":"2019-04-01","type":"neutral","source":"FDA Orange Book","milestone":"Generic entry — 19 manufacturers approved"}],"aiSummary":"Xyzal, also known as levocetirizine, is a small molecule medication used to treat conditions such as seasonal and perennial allergic rhinitis, as well as atopic dermatitis. It is available in oral tablet form and is typically taken once daily.","approvals":[{"date":"2007-05-25","orphan":false,"company":"UCB INC","regulator":"FDA"}],"brandName":"Xyzal","ecosystem":[{"indication":"Allergic rhinitis","otherDrugs":[{"name":"acrivastine","slug":"acrivastine","company":"Auxilium Pharms Inc"},{"name":"alimemazine","slug":"alimemazine","company":"Allergan Herbert"},{"name":"antazoline","slug":"antazoline","company":"Novartis"},{"name":"astemizole","slug":"astemizole","company":""}],"globalPrevalence":null},{"indication":"Chronic idiopathic urticaria","otherDrugs":[{"name":"astemizole","slug":"astemizole","company":""},{"name":"cetirizine","slug":"cetirizine","company":"J And J Consumer Inc"},{"name":"desloratadine","slug":"desloratadine","company":"Merck Sharp Dohme"},{"name":"fexofenadine","slug":"fexofenadine","company":"Sanofi Aventis Us"}],"globalPrevalence":68000000},{"indication":"Seasonal allergic rhinitis","otherDrugs":[{"name":"acrivastine","slug":"acrivastine","company":"Auxilium Pharms Inc"},{"name":"azatadine","slug":"azatadine","company":""},{"name":"azelastine","slug":"azelastine","company":"Meda Pharms"},{"name":"brompheniramine","slug":"brompheniramine","company":""}],"globalPrevalence":null}],"mechanism":{"target":"Histamine H1 receptor","novelty":"Follow-on","targets":[{"gene":"HRH1","source":"DrugCentral","target":"Histamine H1 receptor","protein":"Histamine H1 receptor"}],"moaClass":"Histamine H1 Receptor Antagonists","modality":"Small Molecule","drugClass":"Histamine-1 Receptor Antagonist","explanation":"","oneSentence":"","technicalDetail":"Levocetirizine selectively and competitively binds to the histamine H1 receptor, inhibiting the action of histamine and reducing the symptoms associated with allergic reactions."},"_wikipedia":{"url":"https://en.wikipedia.org/wiki/Levocetirizine","title":"Levocetirizine","extract":"Levocetirizine, sold under the brand name Xyzal, among others, is a second-generation antihistamine used for the treatment of allergic rhinitis and long-term hives of unclear cause. It is less sedating than older antihistamines. It is taken by mouth.","wiki_history":"== History ==\nLevocetirizine was first launched in 2001 by the Belgian pharmaceutical company UCB (Union Chimique Belge).","wiki_society_and_culture":"== Society and culture ==\n\n=== Availability ===\nIn January 2017, the US Food and Drug Administration approved an over-the-counter preparation. Levocetirizine had previously received authorization by the FDA as a prescription drug in 2007, having already been brought to market throughout much of Europe. In India, a prescription-only drug containing levocetirizine hydrochloride and montelukast is sold as Crohist MK.\n\n=== Brand names ===\n\n260px|right|thumb|Different brands ([[Actavis, Glenmark, UCB) Levocetirizine tablets and oral solution]]\nthumb|260px|right|Xyzal Tablets 5mg in [[Japan]]\n\nPreparations of levocetirizine are sold under the following brand names:\n* Xyzal  in Australia, Austria, Bulgaria, Croatia, Cyprus, Czech Republic, Finland, France, Hong Kong, Hungary, India, Ireland (also Rinozal), Italy, Japan, Lithuania, Netherlands, Poland, Portugal, Romania, Taiwan, Thailand, Turkey, The Philippines, Serbia, Singapore, Slovakia, Slovenia, South Africa, Switzerland and UK. In May 2007, the US Food and Drug Administration approved Xyzal, where it is co-marketed by Sanofi-Aventis.\n* Xazal in Spain.\n* Avocel, Histrine Levo, and Xybat in Indonesia\n* Zobral in Cyprus.\n* Levobert in India.\n* Xusal in Germany and Mexico.\n* Xozal in Greece.\n* Degraler in Chile.\n* Allevo in Egypt.\n* Zilola, Histisynt, and Xyzal (UCB) in Hungary.\n* Alcet, Curin, and Seasonix in Bangladesh.\n* Vozet and Uvnil in India.\n* T-Day Syrup in Pakistan.\n* Curin in Nepal.\n* Zenaro in the Czech Republic and Slovakia.\n* Xuzal and Zival in Chile.\n* Cezera, Levosetil, Robenan, and Xyzal in Serbia.\n* Rinozal and Xyzal in Ireland.\n* Xycet in Morocco."},"commercial":{"launchDate":"2007","_launchSource":"DrugCentral (FDA 2007-05-25, UCB INC)"},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/1566","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://clinicaltrials.gov/search?intr=LEVOCETIRIZINE","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":3,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=LEVOCETIRIZINE","fields":["publications"],"source":"PubMed/NCBI"},{"id":4,"url":"https://en.wikipedia.org/wiki/Levocetirizine","fields":["history","overview"],"source":"Wikipedia"},{"id":5,"url":"https://www.fda.gov/drugs/drug-approvals-and-databases/orange-book-data-files","fields":["patents","exclusivity","genericManufacturers"],"source":"FDA Orange Book"}],"_enrichedAt":"2026-03-30T12:19:11.046956","_validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T00:35:43.993044+00:00","fieldsConflicting":2,"overallConfidence":0.8},"biosimilars":[],"competitors":[{"drugName":"buclizine","drugSlug":"buclizine","fdaApproval":"","patentStatus":"Unknown","relationship":"same-class"},{"drugName":"cyclizine","drugSlug":"cyclizine","fdaApproval":"","patentStatus":"Unknown","relationship":"same-class"},{"drugName":"chlorcyclizine","drugSlug":"chlorcyclizine","fdaApproval":"","relationship":"same-class"},{"drugName":"meclozine","drugSlug":"meclozine","fdaApproval":"1957-02-14","relationship":"same-class"},{"drugName":"cetirizine","drugSlug":"cetirizine","fdaApproval":"1995-12-08","patentExpiry":"Sep 15, 2030","patentStatus":"Patent protected","relationship":"same-class"}],"dataSources":[{"url":"https://data.medicaid.gov/dataset/4j6z-xnwq","name":"CMS National Average Drug Acquisition Cost (NADAC)","fields":["pricing"],"retrievedDate":"2026-04-07"}],"genericName":"levocetirizine","indications":{"approved":[{"name":"Allergic rhinitis","source":"DrugCentral","snomedId":61582004,"regulator":"FDA"},{"name":"Chronic idiopathic urticaria","source":"DrugCentral","snomedId":302162004,"regulator":"FDA","usPrevalence":null,"globalPrevalence":68000000,"prevalenceMethod":"curated","prevalenceSource":"Allergy, 2020 (PMID:31494963)"},{"name":"Seasonal allergic rhinitis","source":"DrugCentral","snomedId":367498001,"regulator":"FDA"}],"offLabel":[{"name":"Atopic dermatitis","source":"DrugCentral","drugName":"LEVOCETIRIZINE","evidenceCount":12,"evidenceLevel":"moderate"},{"name":"Urticaria","source":"DrugCentral","drugName":"LEVOCETIRIZINE"}],"pipeline":[]},"currentOwner":"Chattem Sanofi","drugCategory":"mature","labelChanges":[],"patentStatus":"Off-patent — no active Orange Book patents","relatedDrugs":[{"drugId":"buclizine","brandName":"buclizine","genericName":"buclizine","approvalYear":"","relationship":"same-class"},{"drugId":"cyclizine","brandName":"cyclizine","genericName":"cyclizine","approvalYear":"","relationship":"same-class"},{"drugId":"chlorcyclizine","brandName":"chlorcyclizine","genericName":"chlorcyclizine","approvalYear":"","relationship":"same-class"},{"drugId":"meclozine","brandName":"meclozine","genericName":"meclozine","approvalYear":"1957","relationship":"same-class"},{"drugId":"cetirizine","brandName":"cetirizine","genericName":"cetirizine","approvalYear":"1995","relationship":"same-class"}],"trialDetails":[{"nctId":"NCT07299695","phase":"PHASE3","title":"Intravenous Immunoglobulin for the Treatment of Acute Exacerbations of Idiopathic Pulmonary Fibrosis","status":"RECRUITING","sponsor":"Argyrios Tzouvelekis","startDate":"2026-01-25","conditions":["Idiopathic Pulmonary Fibrosis","Acute Exacerbation of Idiopathic Pulmonary Fibrosis"],"enrollment":196,"completionDate":"2028-12"},{"nctId":"NCT07341776","phase":"PHASE4","title":"Steroid Use in Treatment of Allergic Reactions to Food","status":"RECRUITING","sponsor":"Johannes Trueck","startDate":"2026-01-26","conditions":["Anaphylactic Reaction","Anaphylaxis","Allergy in Children","IgE Mediated Food Allergy"],"enrollment":160,"completionDate":"2026-12"},{"nctId":"NCT07365683","phase":"NA","title":"Efficacy of Bilastine Up-dosing (40 mg ) Versus Combination of Bilastine (20 mg )With Levocitirizine (5 mg) in the Treatment of Chronic Spontaneous Urticaria","status":"COMPLETED","sponsor":"Derma Techno Pakistan","startDate":"2025-08-18","conditions":["Chronic Spontaneous Urticaria (CSU)"],"enrollment":60,"completionDate":"2026-01-17"},{"nctId":"NCT07323888","phase":"NA","title":"Traditional vs. Posterior Nasal Radiofrequency Ablation for Chronic Rhinitis","status":"NOT_YET_RECRUITING","sponsor":"Chien Yu Huang","startDate":"2026-01","conditions":["Nasal Obstruction","Chronic Rhinitis","Nonallergic Rhinitis","Rhinorrhea","Inferior Turbinate Hypertrophy"],"enrollment":60,"completionDate":"2027-12"},{"nctId":"NCT05637710","phase":"PHASE3","title":"Parallel, Double-dummy, Superiority Study Levocetirizine/Pseudoephedrine x Zina for Allergic Rhinitis in Brazil","status":"WITHDRAWN","sponsor":"Eurofarma Laboratorios S.A.","startDate":"2026-03","conditions":["Allergic Rhinitis"],"enrollment":0,"completionDate":"2027-05"},{"nctId":"NCT03545464","phase":"PHASE3","title":"COrticosteroids in acUte uRticAria in emerGency dEpartment","status":"COMPLETED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2019-09-21","conditions":["Urticaria","Angiœdema"],"enrollment":137,"completionDate":"2025-09-17"},{"nctId":"NCT04699604","phase":"PHASE3","title":"A Histamine Pharmacodynamic Biomarker to Guide Treatment in Pediatric Asthma (HAS3)","status":"RECRUITING","sponsor":"Bridgette Jones","startDate":"2021-04-28","conditions":["Allergic Asthma"],"enrollment":300,"completionDate":"2026-05-01"},{"nctId":"NCT06632405","phase":"PHASE2","title":"A Trial of Camrelizumab Plus Nab-paclitaxel and Levocetirizine in Metastatic or Recurrent TNBC","status":"NOT_YET_RECRUITING","sponsor":"Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University","startDate":"2025-04-01","conditions":["Breast Cancer"],"enrollment":60,"completionDate":"2027-03-31"},{"nctId":"NCT06816784","phase":"PHASE2","title":"Treatment Options for Chronic Urticaria","status":"NOT_YET_RECRUITING","sponsor":"Sheikh Zayed Medical College","startDate":"2025-02","conditions":["Chronic Urticaria"],"enrollment":72,"completionDate":"2025-07"},{"nctId":"NCT00789152","phase":"PHASE3","title":"The Effect of Desloratadine and Levocetirizine on Nasal Obstruction (Study P03609)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2003-12-01","conditions":["Allergic Rhinitis"],"enrollment":81,"completionDate":"2004-05-01"},{"nctId":"NCT05638880","phase":"PHASE2","title":"Clinical Study to Evaluate the Possible Efficacy and Safety of Levocetirizine in Patients With Diabetic Kidney Disease","status":"RECRUITING","sponsor":"Mostafa Bahaa","startDate":"2022-12-20","conditions":["Diabetic Nephropathies"],"enrollment":60,"completionDate":"2026-10-20"},{"nctId":"NCT05565729","phase":"PHASE1","title":"A Phase I Study of LY3471851 in Healthy Participants","status":"COMPLETED","sponsor":"Nektar Therapeutics","startDate":"2022-10-05","conditions":["Healthy"],"enrollment":41,"completionDate":"2023-02-23"},{"nctId":"NCT00160680","phase":"PHASE4","title":"ATAREAL (Antihistamine Treatment for Allergic Rhinitis in Real Life)","status":"COMPLETED","sponsor":"UCB S.A. - Pharma Sector","startDate":"2005-03-01","conditions":["Rhinitis, Allergic, Perennial"],"enrollment":62,"completionDate":"2006-06-01"},{"nctId":"NCT05348148","phase":"NA","title":"Comparison of the Effects for Lightening the Shiners Among Different Treatments for Rhinitis","status":"RECRUITING","sponsor":"Camillians Saint Mary's Hospital Luodong","startDate":"2020-06-16","conditions":["Allergic Rhinitis","Vasomotor Rhinitis"],"enrollment":450,"completionDate":"2032-03-31"},{"nctId":"NCT00359138","phase":"PHASE4","title":"The Duration of the Suppressive Effects of Desloratadine on Allergen Prick Tests After Discontinuation (P04441)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2006-02","conditions":["Hypersensitivity"],"enrollment":36,"completionDate":"2006-05"},{"nctId":"NCT01392859","phase":"PHASE2,PHASE3","title":"Characterization of the Role of Histamine in Children With Asthma","status":"COMPLETED","sponsor":"Children's Mercy Hospital Kansas City","startDate":"2011-06","conditions":["Asthma","Allergic Asthma","Non-allergic Asthma"],"enrollment":211,"completionDate":"2015-03-29"},{"nctId":"NCT03789422","phase":"PHASE4","title":"Tranexamic Acid and Spontaneous Chronic Urticaria","status":"UNKNOWN","sponsor":"University Hospital, Grenoble","startDate":"2019-12-10","conditions":["Chronic Spontaneous Urticaria"],"enrollment":80,"completionDate":"2022-09"},{"nctId":"NCT00621959","phase":"PHASE4","title":"A Study Evaluating the Efficacy and Impact on Health-related Quality of Life of Levocetirizine in Adults With Seasonal Allergic Rhinitis","status":"COMPLETED","sponsor":"UCB Pharma","startDate":"2008-03","conditions":["Seasonal Allergic Rhinitis"],"enrollment":596,"completionDate":"2008-06"},{"nctId":"NCT03590912","phase":"PHASE4","title":"Efficacy and Cost Analysis of Steroids in Treatment of Otitis Media With Effusion","status":"COMPLETED","sponsor":"Lumbini Medical College","startDate":"2018-09-05","conditions":["Otitis Media With Effusion"],"enrollment":160,"completionDate":"2020-03-18"},{"nctId":"NCT03555890","phase":"PHASE1","title":"Bioequivalence Study Between Levocetirizine Oral Disintegrating Tablet (ODT) and Levocetirizine Immediate Release Tablet (IRT)","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2018-05-18","conditions":["Rhinitis"],"enrollment":72,"completionDate":"2018-09-17"},{"nctId":"NCT04399525","phase":"NA","title":"Influence of H1-antihistamines on the Dermal Blood Flow Response to Histamine, Cinnamaldehyde and Capsaicin.","status":"COMPLETED","sponsor":"Universitaire Ziekenhuizen KU Leuven","startDate":"2019-10-28","conditions":["Pruritus"],"enrollment":12,"completionDate":"2020-03-12"},{"nctId":"NCT04324918","phase":"PHASE3","title":"Efficacy and Safety of HCP1102 Capsule in Patients With Perennial Allergic Rhinitis","status":"COMPLETED","sponsor":"Hanmi Pharmaceutical Company Limited","startDate":"2018-10-23","conditions":["Perennial Allergic Rhinitis"],"enrollment":174,"completionDate":"2019-06-24"},{"nctId":"NCT01586091","phase":"PHASE4","title":"Safety Study of Levocetirizine and Fexofenadine","status":"COMPLETED","sponsor":"Charite University, Berlin, Germany","startDate":"2011-02","conditions":["Pruritus","Chronic Urticaria","Allergic Rhinitis"],"enrollment":18,"completionDate":"2012-02"},{"nctId":"NCT03991845","phase":"PHASE4","title":"A Trial to Evaluate the Effect of Vitamin D Supplementation in Patients With Chronic Urticaria","status":"UNKNOWN","sponsor":"Post Graduate Institute of Medical Education and Research, Chandigarh","startDate":"2019-06-21","conditions":["Urticaria","Vitamin D Deficiency"],"enrollment":262,"completionDate":"2019-12-28"},{"nctId":"NCT00679250","phase":"PHASE4","title":"To Evaluate Adenosine Monophosphate and Allergen Challenge in Allergic Rhinitis","status":"COMPLETED","sponsor":"Brian J Lipworth","startDate":"2005-11","conditions":["Allergic Rhinitis"],"enrollment":25,"completionDate":"2006-12"},{"nctId":"NCT00152464","phase":"PHASE3","title":"Prevention of Asthma With Levocetirizine 18 Month Treatment in Infants (12 - 24 Months) Suffering From Eczema (Atopic Dermatitis) and Sensitized to Grass Pollen and/or House Dust Mite (HDM)","status":"COMPLETED","sponsor":"UCB Pharma SA","startDate":"2002-03-20","conditions":["Dermatitis, Atopic"],"enrollment":514,"completionDate":"2006-03-15"},{"nctId":"NCT02372604","phase":"PHASE3","title":"Efficacy of Levocetirizine Fourfold Dosage in Chronic Spontaneous Urticaria","status":"COMPLETED","sponsor":"Hospices Civils de Lyon","startDate":"2015-07","conditions":["Chronic Spontaneous Urticaria"],"enrollment":15,"completionDate":"2016-12"},{"nctId":"NCT03673384","phase":"NA","title":"Effect of Health Promotion on Allergic Rhinitis by Infrared-C Ray Irradiation","status":"COMPLETED","sponsor":"Nanhua University","startDate":"2015-03-02","conditions":["Allergic Rhinitis"],"enrollment":50,"completionDate":"2017-07-30"},{"nctId":"NCT00295022","phase":"PHASE4","title":"Compare the Efficacy of Levocetirizine and Montelukast to Placebo in Reducing Seasonal Allergic Rhinitis (SAR) Symptoms in Ragweed Sensitive Subjects","status":"COMPLETED","sponsor":"UCB S.A. - Pharma Sector","startDate":"2006-07-29","conditions":["Rhinitis, Allergic, Seasonal"],"enrollment":418,"completionDate":"2006-10-01"},{"nctId":"NCT00291642","phase":"PHASE2","title":"A Study to Compare the Efficacy of Levocetirizine to Placebo in Reducing Symptoms of Seasonal Allergic Rhinitis (SAR) in Sensitive Subjects Exposed to Ragweed Pollen","status":"COMPLETED","sponsor":"UCB Pharma","startDate":"2006-01-01","conditions":["Rhinitis","Allergic","Seasonal"],"enrollment":551,"completionDate":"2006-04-01"},{"nctId":"NCT03250143","phase":"PHASE1,PHASE2","title":"To Assess and Compare the Efficacy of Cyclosporine Versus Azathioprine in the Treatment of Chronic Refractory Urticaria","status":"COMPLETED","sponsor":"Post Graduate Institute of Medical Education and Research, Chandigarh","startDate":"2016-12-06","conditions":["Chronic Refractory Urticaria"],"enrollment":56,"completionDate":"2017-11"},{"nctId":"NCT03371849","phase":"PHASE1","title":"PK and Safety Study of HCP1102, HGP0813 and HGP1408","status":"COMPLETED","sponsor":"Hanmi Pharmaceutical Company Limited","startDate":"2017-07-19","conditions":["Healthy"],"enrollment":24,"completionDate":"2017-08-03"},{"nctId":"NCT02447393","phase":"PHASE1","title":"Phase 1 Study of Levocetirizine","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2008-03-18","conditions":["Dermatitis"],"enrollment":20,"completionDate":"2008-04-30"},{"nctId":"NCT00866788","phase":"PHASE2","title":"A Study of Xolair (Omalizumab) in Patients With Chronic Idiopathic Urticaria (CIU) Who Remain Symptomatic With Antihistamine Treatment (H1)","status":"COMPLETED","sponsor":"Genentech, Inc.","startDate":"2009-03","conditions":["Chronic Idiopathic Urticaria"],"enrollment":90,"completionDate":"2010-01"},{"nctId":"NCT01622283","phase":"PHASE1","title":"Pharmacokinetic Study of Levocetirizine Oral Solution","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2012-05-02","conditions":["Rhinitis, Allergic, Perennial and Seasonal"],"enrollment":20,"completionDate":"2012-06-10"},{"nctId":"NCT01722162","phase":"PHASE2","title":"Levocetirizine + Capecitabine + Bevacizumab for Patients With Refractory Colorectal Cancer","status":"COMPLETED","sponsor":"Washington University School of Medicine","startDate":"2013-04","conditions":["Colorectal Neoplasms"],"enrollment":47,"completionDate":"2015-10"},{"nctId":"NCT01563081","phase":"PHASE3","title":"Safety Study of Levocetirizine Oral Solution for Japanese Pediatrics","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2012-04","conditions":["Rhinitis"],"enrollment":60,"completionDate":"2012-08"},{"nctId":"NCT01008592","phase":"","title":"The Effect of Levocetirizine on Inflammatory Mediators in Dermatographism","status":"TERMINATED","sponsor":"Wake Forest University","startDate":"2009-04","conditions":["Rhinitis","Urticaria"],"enrollment":11,"completionDate":"2010-09"},{"nctId":"NCT02551536","phase":"PHASE4","title":"Montelukast and Fexofenadine Versus Montelukast and Levocetrizine Combination in Allergic Rhinitis","status":"COMPLETED","sponsor":"Indira Gandhi Medical College, Shimla","startDate":"2014-04","conditions":["Allergic Rhinitis"],"enrollment":70,"completionDate":"2015-06"},{"nctId":"NCT01445262","phase":"","title":"Drug Use Investigation for XYZAL®","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2011-02","conditions":["Rhinitis, Allergic, Perennial and Seasonal"],"enrollment":10728,"completionDate":"2013-12"},{"nctId":"NCT02507635","phase":"PHASE4","title":"Anti-inflammatory H1 Antihistamines Allergic Rhinitis","status":"COMPLETED","sponsor":"Iuliu Hatieganu University of Medicine and Pharmacy","startDate":"2009-02","conditions":["Allergic Rhinitis"],"enrollment":115,"completionDate":"2013-05"},{"nctId":"NCT00619801","phase":"PHASE3","title":"Safety Study of Levocetirizine Dihydrochloride Oral Liquid Formulation in Children Aged 1 to Less Than 6 Years Suffering From Allergic Rhinitis or Chronic Urticaria of Unknown Origin","status":"COMPLETED","sponsor":"UCB Pharma","startDate":"2008-03","conditions":["Allergic Rhinitis","Chronic Urticaria"],"enrollment":173,"completionDate":"2008-07"},{"nctId":"NCT00628108","phase":"PHASE3","title":"Safety Study of Levocetirizine Dihydrochloride Oral Liquid Formulation in Children Aged 6 Months to 11 Months","status":"COMPLETED","sponsor":"UCB Pharma","startDate":"2008-03","conditions":["Allergic Rhinitis","Chronic Urticaria"],"enrollment":69,"completionDate":"2008-09"},{"nctId":"NCT00160563","phase":"PHASE3","title":"Prevention of Asthma With Levocetirizine (36 Month Treatment) in Young Children Suffering From Eczema (Atopic Dermatitis) and Sensitized to Grass Pollen and House Dust Mite and Having Completed the Previous EPAAC Trial (NCT00152464)","status":"TERMINATED","sponsor":"UCB Pharma","startDate":"2004-06","conditions":["Asthma"],"enrollment":207,"completionDate":"2006-03"},{"nctId":"NCT00150761","phase":"PHASE4","title":"Facial Thermography Study of Levocetirizine Versus Cetirizine","status":"COMPLETED","sponsor":"UCB Pharma","startDate":"2004-07","conditions":["Anti-allergic Agents"],"enrollment":60,"completionDate":"2004-10"},{"nctId":"NCT00152412","phase":"PHASE2","title":"Open Study to Evaluate the Safety of Levocetirizine in Young Children (2 - 6 Years) Suffering From Allergic Rhinitis","status":"COMPLETED","sponsor":"UCB Pharma","startDate":"2004-06","conditions":["Allergic Rhinitis"],"enrollment":30,"completionDate":"2004-12"},{"nctId":"NCT00826943","phase":"PHASE4","title":"Is Levocetirizine Less Sedating Than Cetirizine?","status":"COMPLETED","sponsor":"Vanderbilt University","startDate":"2009-01","conditions":["Allergic Rhinitis"],"enrollment":30,"completionDate":"2009-05"},{"nctId":"NCT00521170","phase":"PHASE1","title":"Wheal and Flare Reaction During 24 Hours in Allergic Volunteers.","status":"COMPLETED","sponsor":"UCB Pharma","startDate":"2004-11","conditions":["Allergy"],"enrollment":0,"completionDate":"2005-01"},{"nctId":"NCT00544388","phase":"PHASE3","title":"Efficacy of Levocetirizine and Cetirizine in Reducing Symptoms of Seasonal Allergic Rhinitis in Ragweed Sensitive Subjects","status":"COMPLETED","sponsor":"UCB Pharma","startDate":"2004-04","conditions":["Rhinitis, Allergic, Seasonal"],"enrollment":570,"completionDate":"2004-07"},{"nctId":"NCT00160589","phase":"PHASE4","title":"LEADER (LEvocetirizine And DEsloratadine in Allergic Rhinitis)","status":"COMPLETED","sponsor":"UCB Pharma","startDate":"2005-04","conditions":["Rhinitis, Allergic, Perennial"],"enrollment":729,"completionDate":"2005-09"},{"nctId":"NCT00525278","phase":"PHASE3","title":"To Evaluate the Efficacy and Safety of Levocetirizine Versus Loratadine for Treatment of Seasonal Allergic Rhinitis","status":"COMPLETED","sponsor":"UCB Pharma","startDate":"2003-08","conditions":["Rhinitis","Allergic","Seasonal"],"enrollment":67,"completionDate":"2003-10"},{"nctId":"NCT00524836","phase":"PHASE3","title":"Efficacy and Safety of Levocetirizine Versus Loratadine for the Treatment of Perennial Allergic Rhinitis","status":"COMPLETED","sponsor":"UCB Pharma","startDate":"2003-09","conditions":["Rhinitis","Allergic","Perennial"],"enrollment":71,"completionDate":"2004-02"},{"nctId":"NCT00521131","phase":"PHASE4","title":"Evaluation of Efficacy and Safety of Levocetirizine to Subjects With Perennial Allergic Rhinitis to House Dust Mites","status":"COMPLETED","sponsor":"UCB Pharma","startDate":"2002-09","conditions":["Rhinitis","Allergic","Perennial"],"enrollment":453,"completionDate":"2003-05"},{"nctId":"NCT00315523","phase":"PHASE3","title":"Compare the Efficacy of Levocetirizine to Montelukast in Reducing Symptoms of SAR in Sensitive Subjects Exposed to Ragweed Pollen","status":"COMPLETED","sponsor":"UCB Pharma","startDate":"2006-07","conditions":["Rhinitis, Allergic, Seasonal"],"enrollment":403,"completionDate":"2006-10"},{"nctId":"NCT00160537","phase":"PHASE4","title":"POPULAR (Preference Of Patient Using Levocetirizine in Allergic Rhinitis)","status":"COMPLETED","sponsor":"UCB Pharma","startDate":"2005-05","conditions":["Seasonal Allergic Rhinitis"],"enrollment":200,"completionDate":"2005-07"},{"nctId":"NCT00542607","phase":"PHASE4","title":"Efficacy and Safety of Levocetirizine and Fexofenadine in Reducing Symptoms of Seasonal Allergic Rhinitis","status":"COMPLETED","sponsor":"UCB Pharma","startDate":"2002-09","conditions":["Rhinitis, Allergic, Seasonal"],"enrollment":94,"completionDate":"2002-12"},{"nctId":"NCT00525382","phase":"PHASE3","title":"Study to Compare the Efficacy and Safety Between Levocetirizine and Loratadine for Chronic Idiopathic Urticaria","status":"COMPLETED","sponsor":"UCB Pharma","startDate":"2003-08","conditions":["Urticaria"],"enrollment":134,"completionDate":"2004-03"},{"nctId":"NCT00521040","phase":"NA","title":"Efficacy and Safety of Levocetirizine 8 Weeks Prior and After the Onset of the Grass Pollen Season in Subjects With SAR","status":"COMPLETED","sponsor":"UCB Pharma","startDate":"2004-02","conditions":["Rhinitis, Allergic, Seasonal"],"enrollment":459,"completionDate":"2004-07"},{"nctId":"NCT00520754","phase":"PHASE2","title":"Efficacy and Safety of Levocetirizine for Treatment of Recurrent Cough Associated With Other Allergic Symptoms in Children","status":"COMPLETED","sponsor":"UCB Pharma","startDate":"2001-12","conditions":["Cough"],"enrollment":15,"completionDate":"2003-03"},{"nctId":"NCT01496911","phase":"PHASE4","title":"Effects of Levocetirizine and Hydroxyzine on Cognitive and Psychomotor Functioning During Simulated Diving","status":"COMPLETED","sponsor":"Utrecht Institute for Pharmaceutical Sciences","startDate":"2012-04","conditions":["Healthy Volunteers"],"enrollment":24,"completionDate":"2012-10"},{"nctId":"NCT00884325","phase":"PHASE4","title":"Management of Pruritus With Xyzal in Atopic Dermatitis","status":"COMPLETED","sponsor":"Derm Research, PLLC","startDate":"2009-02","conditions":["Atopic Dermatitis","Pruritus"],"enrollment":40,"completionDate":"2010-01"},{"nctId":"NCT01651481","phase":"PHASE1","title":"Study to Evaluate the Pharmacokinetics and Safety of Singulair and Xyzal in Free Combination and Fixed-dose Combination","status":"COMPLETED","sponsor":"Hanmi Pharmaceutical Company Limited","startDate":"2012-07","conditions":["Rhinitis"],"enrollment":28,"completionDate":"2012-12"},{"nctId":"NCT01250652","phase":"PHASE4","title":"Levocetirizine Plus Bed-Time Hydroxyzine in the Management of Corticodependent Chronic Urticaria Versus Levocetirizine Alone in High Doses","status":"COMPLETED","sponsor":"Association Asthma, Bulgaria","startDate":"2011-03","conditions":["Chronic Urticaria"],"enrollment":24,"completionDate":"2013-03"},{"nctId":"NCT01509209","phase":"PHASE3","title":"Efficacy/Safety of Pseudoephedrine Plus Levocetirizine Versus Placebo in Patients With Vasomotor Rhinitis","status":"COMPLETED","sponsor":"Hanmi Pharmaceutical Company Limited","startDate":"2011-05","conditions":["Vasomotor Rhinitis"],"enrollment":137,"completionDate":"2013-04"},{"nctId":"NCT01640535","phase":"PHASE3","title":"Efficacy and Safety of Concomitant Montelukast Sodium and Levocetirizine Dihydrochloride in Perennial Allergic Rhinitis (PAR) Patients","status":"COMPLETED","sponsor":"Hanmi Pharmaceutical Company Limited","startDate":"2012-06","conditions":["Perennial Allergic Rhinitis"],"enrollment":283,"completionDate":"2013-02"},{"nctId":"NCT01491503","phase":"PHASE1","title":"A Drug Interaction Study of Montelukast and Levocetirizine","status":"COMPLETED","sponsor":"Hanmi Pharmaceutical Company Limited","startDate":"2011-11","conditions":["Healthy"],"enrollment":30,"completionDate":"2012-01"},{"nctId":"NCT01567501","phase":"PHASE1","title":"Bioequivalence Study of Levocetirizine Dihydrochloride Tablets 5 mg Under Fed Condition","status":"COMPLETED","sponsor":"IPCA Laboratories Ltd.","startDate":"2012-02","conditions":["Fed"],"enrollment":28,"completionDate":"2012-03"},{"nctId":"NCT01557439","phase":"PHASE1","title":"Bioequivalence Study of Levocetirizine Dihydrochloride Tablets 5 mg Under Fasting Condition","status":"COMPLETED","sponsor":"IPCA Laboratories Ltd.","startDate":"2012-02","conditions":["Fasting State"],"enrollment":28,"completionDate":"2012-03"},{"nctId":"NCT01430260","phase":"PHASE4","title":"Omnaris Versus Levocetirizine Phase 4 Study","status":"COMPLETED","sponsor":"Handok Inc.","startDate":"2011-01","conditions":["Allergic Rhinitis"],"enrollment":349,"completionDate":"2012-07"},{"nctId":"NCT00598780","phase":"","title":"Evaluation of Safety of Levocetirizine in Routine Clinical Practice-non- Interventional Study","status":"COMPLETED","sponsor":"UCB Pharma","startDate":"2007-09","conditions":["Rhinitis Allergic, Persistent"],"enrollment":7870,"completionDate":"2008-09"},{"nctId":"NCT00421109","phase":"PHASE3","title":"Efficacy Study for the Symptomatic Treatment of Chronic Idiopathic Urticaria","status":"COMPLETED","sponsor":"Faes Farma, S.A.","startDate":"2006-07","conditions":["Urticaria"],"enrollment":522,"completionDate":"2007-07"},{"nctId":"NCT01506063","phase":"PHASE1","title":"Bioequivalence Study of Levocetirizine DiHCl Tablets 5mg of Dr. Reddy's Under Fed Conditions","status":"COMPLETED","sponsor":"Dr. Reddy's Laboratories Limited","startDate":"2008-01","conditions":["Healthy"],"enrollment":31,"completionDate":"2008-01"},{"nctId":"NCT01506076","phase":"PHASE1","title":"Bioequivalence Study of Levocetirizine DiHCl Tablets 5mg of Dr. Reddy's Under Fasting Conditions","status":"COMPLETED","sponsor":"Dr. Reddy's Laboratories Limited","startDate":"2007-12","conditions":["Fasting"],"enrollment":29,"completionDate":"2008-01"},{"nctId":"NCT00653224","phase":"PHASE4","title":"A Study Evaluating the Efficacy and Impact on Health-related Quality of Life of Levocetirizine in Adults With Seasonal Allergic Rhinitis","status":"COMPLETED","sponsor":"UCB Pharma","startDate":"2008-04","conditions":["Seasonal Allergic Rhinitis"],"enrollment":580,"completionDate":"2008-07"},{"nctId":"NCT00375713","phase":"PHASE3","title":"Randomized Phase III Study to Evaluate the Efficacy and Safety of Xyzal® (Levocetirizine) vs Zyrtec® (Cetirizine) in Subjects With Dermatitis and Eczema","status":"COMPLETED","sponsor":"UCB Pharma","startDate":"2005-10","conditions":["Dermatitis","Eczema"],"enrollment":466,"completionDate":"2006-05"},{"nctId":"NCT00264303","phase":"PHASE4","title":"CUTE (Chronic Urticaria Treatment Evaluation)","status":"COMPLETED","sponsor":"UCB Pharma","startDate":"2005-12","conditions":["Chronic Idiopathic Urticaria"],"enrollment":886,"completionDate":"2007-01"},{"nctId":"NCT01000792","phase":"PHASE3","title":"3-D Visualization of the Anti-Obstructive Effect of Levocetirizine","status":"COMPLETED","sponsor":"Clinical Research International Limited","startDate":"2009-11","conditions":["Allergic Rhinitis"],"enrollment":1,"completionDate":"2010-07"},{"nctId":"NCT01062139","phase":"PHASE4","title":"Cosalin® Monotherapy Versus Cosalin® and Xarlin® Combination Therapy","status":"UNKNOWN","sponsor":"HK inno.N Corporation","startDate":"2009-10","conditions":["Perennial Allergic Rhinitis"],"enrollment":100,"completionDate":""},{"nctId":"NCT00894231","phase":"PHASE4","title":"Levocetirizine Effect on Nasal Nitric Oxide and Nasal Eosinophils in Subjects With Perennial Allergic Rhinitis","status":"COMPLETED","sponsor":"AAADRS Clinical Research Center","startDate":"2009-01","conditions":["Perennial Allergic Rhinitis"],"enrollment":30,"completionDate":"2009-08"},{"nctId":"NCT00355771","phase":"PHASE4","title":"Levocetirizine 5 mg: Reduction of Symptoms, Airway Resistance and Sleep Impairment in Persistent Allergic Rhinitis","status":"COMPLETED","sponsor":"Institut für Atemwegsforschung GmbH","startDate":"2006-06","conditions":["Allergic Rhinitis"],"enrollment":100,"completionDate":"2007-11"},{"nctId":"NCT00439712","phase":"PHASE4","title":"Levocetirizine in the Treatment of Nasal Obstruction Due to Perennial Allergic Rhinitis","status":"COMPLETED","sponsor":"Institut für Atemwegsforschung GmbH","startDate":"2007-02","conditions":["Perennial Allergic Rhinitis"],"enrollment":60,"completionDate":"2007-05"},{"nctId":"NCT00346606","phase":"PHASE4","title":"The Efficacy and Safety of Desloratadine With Levocetirizine in Treatment of Chronic Idiopathic Urticaria","status":"UNKNOWN","sponsor":"Lotus Pharmaceutical","startDate":"2006-01","conditions":["Chronic Idiopathic Urticaria","Urticaria"],"enrollment":60,"completionDate":""}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"administration":{"route":"Oral","formulation":"Cream, Gel, Shampoo, Solution","formulations":[{"form":"CREAM","route":"TOPICAL","productName":"HYDROCORTISONE 2.5% / LEVOCETIRIZINE DIHYDROCHLORIDE 2%"},{"form":"CREAM","route":"TOPICAL","productName":"LEVOCETIRIZINE DIHYDROCHLORIDE 2% / MUPIROCIN 2% / TRIAMCINOLONE ACETONIDE 0.025%"},{"form":"GEL","route":"TOPICAL","productName":"IMIQUIMOD 5% / LEVOCETIRIZINE DIHYDROCHLORIDE 1% / NIACINAMIDE 2%"},{"form":"GEL","route":"TOPICAL","productName":"IMIQUIMOD 5% / LEVOCETIRIZINE DIHYDROCHLORIDE 1% / TRETINOIN 0.05%"},{"form":"SHAMPOO","route":"TOPICAL","productName":"CLOBETASOL PROPIONATE 0.05% / LEVOCETIRIZINE DIHYDROCHLORIDE 2%"},{"form":"SOLUTION","route":"ORAL","productName":"Levocetirizine Dihydrochloride"},{"form":"SOLUTION","route":"ORAL","productName":"levocetirizine dihydrochloride"},{"form":"SOLUTION","route":"ORAL","productName":"Childrens Xyzal Allergy"},{"form":"SOLUTION","route":"ORAL","productName":"Xyzal"},{"form":"TABLET","route":"ORAL","productName":"ALLERGY RELIEF"},{"form":"TABLET","route":"ORAL","productName":"Allergy Relief 24HR"},{"form":"TABLET","route":"ORAL","productName":"Curist Allergy Relief"},{"form":"TABLET","route":"ORAL","productName":"LEVOCETIRIZINE DIHYDROCHLORIDE"},{"form":"TABLET","route":"ORAL","productName":"Levocetirizine Dihydrochloride"},{"form":"TABLET","route":"ORAL","productName":"Levocetirizine dihydrochloride"}]},"_patentsChecked":true,"crossReferences":{"MMSL":"178562","NDDF":"009491","UNII":"6U5EA9RT2O","CHEBI":"CHEBI:94559","VANDF":"4026739","INN_ID":"7700","RXNORM":"356887","UMLSCUI":"C1174893","chemblId":"CHEMBL1201191","ChEMBL_ID":"CHEMBL1201191","KEGG_DRUG":"D07402","DRUGBANK_ID":"DB06282","PDB_CHEM_ID":"LCR","PUBCHEM_CID":"1549000","SNOMEDCT_US":"391595003","SECONDARY_CAS_RN":"823178-28-5","MESH_SUPPLEMENTAL_RECORD_UI":"C472067"},"formularyStatus":[],"_enricherVersion":"v2","_offLabelChecked":true,"developmentCodes":[],"ownershipHistory":[{"period":"2007-","companyName":"Ucb Inc","relationship":"Original Developer"},{"period":"present","companyName":"Chattem Sanofi","relationship":"Current Owner"}],"publicationCount":558,"therapeuticAreas":["Immunology"],"atcClassification":{"source":"DrugCentral","atcCode":"R06AE09","allCodes":["R06AE09"]},"biosimilarFilings":[],"originalDeveloper":"Ucb Inc","recentPublications":[{"date":"2026 Feb 22","pmid":"41724883","title":"Risk of injury associated with the sedative potential of second-generation antihistamines: A nationwide retrospective cohort study.","journal":"British journal of clinical pharmacology"},{"date":"2026","pmid":"41709973","title":"Comparative Effects of Anti-Inflammatory Therapies on Olfactory Bulb Histopathology and Olfactory Function in a Rat Model of Experimental Allergic Rhinitis.","journal":"Journal of inflammation research"},{"date":"2025","pmid":"41585881","title":"Gender and age variations in neuropsychiatric adverse events of cetirizine and levocetirizine: a disproportionality analysis of ICSRs from FAERS and EudraVigilance data.","journal":"Frontiers in pharmacology"},{"date":"2026 Jan 8","pmid":"41505263","title":"Intramuscular Compound Betamethasone for the Emergent Management of Lingual Angioedema.","journal":"The Journal of craniofacial surgery"},{"date":"2026 Apr","pmid":"41502226","title":"Effect of inhaled corticosteroid with oral montelukast and levocetirizine in asthma: A population-based study.","journal":"International journal of clinical pharmacology and therapeutics"}],"companionDiagnostics":[],"genericManufacturers":20,"_genericFilersChecked":true,"genericManufacturerList":["Apotex","Chartwell Molecular","Dr Reddys","Dr Reddys Labs Ltd","Glenmark Pharms Ltd","Granules","Hetero Labs Ltd Iii","Ipca Labs Ltd","Macleods Pharms Ltd","Micro Labs Ltd India","Padagis Us","Perrigo R And D","Sankalp Lifecare","Sciegen Pharms","Sun Pharm","Sun Pharm Inds Ltd","Synthon Bv","Taro","Teva Pharms","Us Antibiotics"],"status":"approved","companyName":"Chattem Sanofi","companyId":"sanofi","modality":"Small molecule","firstApprovalDate":"2007","enrichmentLevel":3,"visitCount":2,"regulatoryByCountry":[{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":"2007-05-25T00:00:00.000Z","mah":"UCB INC","brand_name_local":null,"application_number":null},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2007-05-25T00:00:00.000Z","mah":"UCB INC","brand_name_local":null,"application_number":""},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2007-05-25T00:00:00.000Z","mah":"CHATTEM SANOFI","brand_name_local":"XYZAL","application_number":"NDA022064"},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":"2007-05-25T00:00:00.000Z","mah":"UCB INC","brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":"2007-05-25T00:00:00.000Z","mah":"UCB INC","brand_name_local":null,"application_number":null},{"country_code":"SA","regulator":"SFDA","status":"likely_approved","approval_date":"2007-05-25T00:00:00.000Z","mah":"UCB INC","brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":"2007-05-25T00:00:00.000Z","mah":"UCB INC","brand_name_local":null,"application_number":null},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2008-01-28T00:00:00.000Z","mah":"CHATTEM SANOFI","brand_name_local":"XYZAL","application_number":"NDA022157"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2019-06-28T00:00:00.000Z","mah":"HETERO LABS LTD III","brand_name_local":null,"application_number":"ANDA091264"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2019-10-25T00:00:00.000Z","mah":"SANKALP LIFECARE","brand_name_local":null,"application_number":"ANDA211551"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2020-07-10T00:00:00.000Z","mah":"PADAGIS US","brand_name_local":null,"application_number":"ANDA091263"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2025-06-10T00:00:00.000Z","mah":"CHARTWELL MOLECULAR","brand_name_local":null,"application_number":"ANDA204599"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2025-07-11T00:00:00.000Z","mah":"HETERO LABS LTD III","brand_name_local":null,"application_number":"ANDA210914"},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"regulatorySummaries":{"US_FDA_approval_28937":{"country_code":"US","agency":"FDA","entity_type":"approval","entity_id":"28937","summary_short":"HETERO LABS LTD III received FDA approval for Xyzal on July 11, 2025, under application number ANDA210914.","summary_long":"The FDA granted marketing authorisation to HETERO LABS LTD III for Xyzal on July 11, 2025. This approval was issued under the standard expedited pathway. The approved indication for Xyzal is listed in the labelling, but the specific indication is not reported. The marketing authorisation holder is HETERO LABS LTD III.","key_points":["HETERO LABS LTD III received FDA approval for Xyzal on July 11, 2025.","The approval was issued under the standard expedited pathway.","The approved indication for Xyzal is listed in the labelling."],"citations":[{"source":"https://api.fda.gov/drug/drugsfda.json?search=application_number:ANDA210914"}],"generated_at":"2026-05-18T08:04:05.755Z"},"US_FDA_approval_28940":{"country_code":"US","agency":"FDA","entity_type":"approval","entity_id":"28940","summary_short":"The FDA granted marketing authorisation to CHARTWELL MOLECULAR for Xyzal on 10 June 2025, under standard expedited pathway.","summary_long":"The FDA granted marketing authorisation to CHARTWELL MOLECULAR for Xyzal on 10 June 2025. This approval was granted under the standard expedited pathway. Xyzal is indicated for the treatment of [insert indication approved, as it is not specified in the provided information].","key_points":["Marketing authorisation holder: CHARTWELL MOLECULAR","Expedited pathway: standard","Approval date: 10 June 2025"],"citations":[{"source":"https://api.fda.gov/drug/drugsfda.json?search=application_number:ANDA204599"}],"generated_at":"2026-05-18T08:06:29.396Z"}},"trialStats":{"total":0,"withResults":0},"validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T00:35:43.993044+00:00","fieldsConflicting":2,"overallConfidence":0.8},"verificationStatus":"verified","dataCompleteness":{"mechanism":false,"indications":true,"safety":true,"trials":true,"score":3}}